Charles River Laboratories International, Inc. $CRL Shares Sold by Balefire LLC

Balefire LLC reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 27.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 9,833 shares of the medical research company’s stock after selling 3,661 shares during the quarter. Balefire LLC’s holdings in Charles River Laboratories International were worth $1,538,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Nuveen LLC bought a new stake in shares of Charles River Laboratories International during the first quarter valued at approximately $18,538,000. Public Sector Pension Investment Board lifted its holdings in shares of Charles River Laboratories International by 113.7% during the first quarter. Public Sector Pension Investment Board now owns 13,659 shares of the medical research company’s stock valued at $2,056,000 after purchasing an additional 7,266 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Charles River Laboratories International by 30.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 862,254 shares of the medical research company’s stock valued at $129,799,000 after purchasing an additional 198,750 shares during the period. Ethic Inc. purchased a new position in Charles River Laboratories International in the 1st quarter worth about $523,000. Finally, American Century Companies Inc. lifted its position in shares of Charles River Laboratories International by 29.1% in the 1st quarter. American Century Companies Inc. now owns 3,853 shares of the medical research company’s stock valued at $580,000 after acquiring an additional 869 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research analyst reports. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Barclays boosted their price objective on Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, October 3rd. Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. lifted their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $194.07.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $195.73 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The stock has a market cap of $9.63 billion, a price-to-earnings ratio of -125.47, a P/E/G ratio of 6.90 and a beta of 1.63. The business’s 50-day simple moving average is $178.81 and its 200 day simple moving average is $164.72. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $200.58.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. During the same period last year, the firm earned $2.59 earnings per share. The business’s revenue for the quarter was down .5% on a year-over-year basis. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).